Brought to life more than half a century ago and successfully applied for high-value petrochemical intermediates production, nickel-catalyzed olefin oligomerization is still a very dynamic topic, with many fundamental questions to address and industrial challenges to overcome. The unique and versatile reactivity of nickel enables the oligomerization of ethylene, propylene and butenes into a wide range of oligomers that are highly sought-after in numerous fields to be controlled. Interestingly, both homogeneous and heterogeneous nickel catalysts have been scrutinized and employed to do this. This rare specificity encouraged us to interlink them in this review so as to open up opportunities for further catalyst development and innovation. An in-depth understanding of the reaction mechanisms in play is essential to being able to fine-tune the selectivity and achieve efficiency in the rational design of novel catalytic systems. This review thus provides a complete overview of the subject, compiling the main fundamental/industrial milestones and remaining challenges facing homogeneous/heterogeneous approaches as well as emerging catalytic concepts, with a focus on the last 10 years.
Alkaloide der Naamin‐Familie wurden in nur zwei Stufen ausgehend von diversen Propargylaminen synthetisiert (siehe Schema: R1=Me, R2=substituierter Benzylrest, R3=Ar). Die Addition eines Propargylamins an ein in situ erzeugtes Carbodiimid, eine Silber(I)‐katalysierte intramolekulare Hydroamidierung und anschließendes Entschützen führen zum zentralen Heterocyclus zahlreicher Naturstoffe und biologisch aktiver Verbindungen. Boc=tert‐Butoxycarbonyl, Cbz=Carbobenzyloxy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.